drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Gene-modified autologous T cells engineered to express a chimeric antigen receptor targeting CD19 for cellular immunotherapy.
nci_thesaurus_concept_id
C125691
nci_thesaurus_preferred_term
Autologous Anti-CD19 CAR-expressing T Lymphocytes
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T lymphocytes bind to and induce selective toxicity against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express an anti-CD19 chimeric antigen receptor; binding to CD19 on B-cell malignancies triggers MHC-independent activation, cytokine release, proliferation, and perforin/granzyme-mediated cytotoxicity, eliminating CD19-positive cells and causing B-cell aplasia.
drug_name
Autologous Anti-CD19 CAR-expressing T Lymphocytes
nct_id_drug_ref
NCT05707273